Kansas
Prescription drug spending and prescribing in Kansas, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $2.4B for prescriptions written in Kansas, the 34th most of 52 states and territories, and 4.1% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $2.4B
- Medicaid drugs, 2025: $400M
- Opioid share of claims: 4.1%
- Life-science raises, 2 years: $13M
How It Prescribes
Medicare Part D, 2024, by the prescriber's state| Share of Part D claims | Kansas | United States | Difference |
|---|---|---|---|
| Opioids | 4.1% | 3.5% | +17% |
| Antibiotics | 4.3% | 4.4% | -2% |
| Antipsychotics | 1.9% | 1.7% | +7% |
Most Distinctive Drugs
Prescribed most out of line with the rest of the country: the drug's share of Kansas's claims against its share nationally| Drug | Against national rate | Claims |
|---|---|---|
| Pen Needle,dual Safety,diabetc | 2.2× | 8,212 |
| Desvenlafaxine Succinate | 2.2× | 20,431 |
| Fentanyl | 2.0× | 16,135 |
| Dofetilide | 2.0× | 6,562 |
| Insulin Aspart (Niacinamide) | 2.0× | 9,444 |
| Sotalol Hcl | 2.0× | 21,835 |
| Vilazodone Hcl | 1.9× | 6,709 |
| Bumetanide | 1.9× | 44,626 |
| Minocycline Hcl | 1.9× | 6,404 |
| Colestipol Hcl | 1.8× | 9,172 |
Biggest Medicaid Drugs
What Kansas's Medicaid program paid pharmacies, before rebates; see every drugLife-Science Fundraising
4 Form D raises by companies based in Kansas in the last two years; the 10 largest. See all raises- Spinal Simplicity, LLC$6M · Biotech · Dec 26, 2024
- Amplifi Vascular, Inc.$6M · Biotech · Nov 27, 2024
- Freedom Health Management, LLC$1M · Other health care · Jul 11, 2025
- Phoreus Biotechnology, Inc.$421K · Biotech · Mar 13, 2026
State Attorney General Health-Care Cases
Antitrust cases Kansas joined, newest first; see every case- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- Connecticut et al. v. Teva Pharmaceuticals et al. Civ. Action No. (D.Conn. Dec. 15, 2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Florida et al. v. Abbott Laboratories et al., No. 1:08-cv-00155-SLR (D.Del. 2007)2007 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- State of Colorado et al v. Warner Chilcott, 1:05-cv-02182 (D.D.C.2005)2005 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
- Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)2004 · Settled
Other States
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG